Predicting heart muscle scarring in patients with mitral valve prolapse
Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse: the SCIMITAR Trial
Centro Cardiologico Monzino · NCT06341166
This study is trying to find out if a new scoring system can help identify patients with mitral valve prolapse who are at risk for heart muscle scarring and related problems using heart imaging.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centro Cardiologico Monzino (other) |
| Locations | 1 site (Milan, Milan) |
| Trial ID | NCT06341166 on ClinicalTrials.gov |
What this trial studies
This multicenter observational study aims to develop a scoring model to predict myocardial fibrosis in patients diagnosed with mitral valve prolapse (MVP) using cardiac magnetic resonance imaging. It will analyze both prospective and retrospective data to identify specific features that may increase the risk of ventricular arrhythmias or sudden cardiac death in these patients. The study seeks to clarify which patients with MVP should undergo cardiac magnetic resonance to detect potential myocardial fibrosis, which is currently uncertain in routine clinical practice.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with an echocardiographic diagnosis of mitral valve prolapse.
Not a fit: Patients under 18 years old or those with other significant heart conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and management of patients with mitral valve prolapse.
How similar studies have performed: Other studies have explored similar predictive models in cardiac conditions, but this specific approach to mitral valve prolapse and myocardial fibrosis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age ≥ 18 years * Echocardiographic diagnosis of mitral valve prolaspe, defined as a systolic displacement of one or both mitral leaflets ≥ 2 mm above the plane of the mitral valve annulus in long-axis views Exclusion Criteria: * age\< 18 years * coexistence of other cardiomyopathies or other ≥ moderate valve diseases * scarce acoustic transthoracic echocardiographic window * usual contraindications for cardiac magnetic resonance
Where this trial is running
Milan, Milan
- Centro Cardiologico Monzino — Milan, Milan, Italy (RECRUITING)
Study contacts
- Study coordinator: Gianluca Pontone, MD
- Email: gianluca.pontone@cardiologicomonzino.it
- Phone: 0258002574
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mitral Valve Prolapse